HHS awards $72.1M contract to Venatorx Pharmaceuticals for novel antibiotic development

Contract Overview

Contract Amount: $72,141,707 ($72.1M)

Contractor: Venatorx Pharmaceuticals Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2022-09-27

End Date: 2028-12-31

Contract Duration: 2,287 days

Daily Burn Rate: $31.5K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 3

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS

Place of Performance

Location: MALVERN, CHESTER County, PENNSYLVANIA, 19355

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $72.1 million to VENATORX PHARMACEUTICALS INC for work described as: VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS Key points: 1. Contract focuses on critical need for new antibiotics against antimicrobial resistance (AMR) and biothreat pathogens. 2. Research and Development in Biotechnology sector, specifically targeting novel drug discovery. 3. Definitive contract type with a Cost Plus Fixed Fee payment structure. 4. Long performance period of 2287 days (over 6 years) indicates a complex, multi-stage R&D effort. 5. Awarded under full and open competition, suggesting a robust market for this type of research. 6. Small business set-aside was not utilized, indicating the scale and nature of the requirement. 7. Geographic focus on Pennsylvania for contract performance.

Value Assessment

Rating: good

The contract value of $72.1 million over more than six years for novel antibiotic R&D appears reasonable given the high-risk, high-reward nature of drug discovery. Benchmarking is difficult without specific details on the research phase and deliverables, but the Cost Plus Fixed Fee structure allows for flexibility while incentivizing cost control through the fixed fee component. The agency's investment aligns with national priorities for combating AMR.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple qualified vendors were likely solicited and had the opportunity to bid. This competitive process is expected to yield fair pricing and innovative solutions. The presence of three bidders (no=3) suggests a healthy level of interest and capability within the market for this specialized R&D.

Taxpayer Impact: Full and open competition generally benefits taxpayers by driving down costs and ensuring the government receives the best value through a wide range of potential solutions.

Public Impact

The primary beneficiaries are public health, through the development of a new antibiotic to combat dangerous pathogens. Services delivered include advanced research and development in biotechnology, focusing on drug discovery and efficacy testing. Geographic impact is primarily in Pennsylvania, where the contractor is located and will perform the work. Workforce implications include specialized jobs in scientific research, development, and pharmaceutical manufacturing.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for cost overruns inherent in R&D projects, though mitigated by the fixed fee component.
Long project duration increases the risk of changing scientific landscapes or regulatory requirements.
Dependence on specific scientific breakthroughs for project success.

Positive Signals

Addresses a critical public health threat (AMR and biothreats), aligning with national security and health priorities.
Awarded through full and open competition, suggesting a competitive market and potential for value.
Cost Plus Fixed Fee structure provides a balance between flexibility for R&D and cost control.
Long-term commitment signals significant agency investment and belief in the project's potential.

Sector Analysis

This contract falls within the Biotechnology R&D sector, a critical area for national health security and economic growth. The market for novel antibiotic development is complex, driven by scientific innovation, regulatory pathways, and significant investment needs. Comparable spending benchmarks are difficult to establish precisely due to the unique nature of R&D, but government investment in this area is substantial and growing due to the increasing threat of antimicrobial resistance.

Small Business Impact

The contract was not awarded as a small business set-aside, which is typical for large-scale, long-term research and development projects requiring significant infrastructure and specialized expertise. There is no explicit information provided regarding subcontracting plans for small businesses, but opportunities may arise for specialized services or materials.

Oversight & Accountability

Oversight will likely be managed by the Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS. Accountability measures will be tied to the Cost Plus Fixed Fee contract terms, requiring regular reporting on research progress, milestones, and expenditures. Transparency is generally maintained through contract awards databases, though specific R&D details may be proprietary.

Related Government Programs

Antimicrobial Resistance Initiatives
Biodefense and Countermeasures
National Institutes of Health (NIH) Research Grants
Biotechnology Research and Development Programs

Risk Flags

R&D Project Risk
Long-Term Contract Duration
Novel Drug Development Uncertainty

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $72.1 million to VENATORX PHARMACEUTICALS INC. VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS

Who is the contractor on this award?

The obligated recipient is VENATORX PHARMACEUTICALS INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $72.1 million.

What is the period of performance?

Start: 2022-09-27. End: 2028-12-31.

What is Venatorx Pharmaceuticals' track record in developing novel antibiotics, particularly for AMR and biothreat pathogens?

Venatorx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing novel antibiotics to combat drug-resistant bacteria. Their lead candidate, cefiderocol (marketed as FACKLOVI®), is approved for complicated urinary tract infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. While cefiderocol targets Gram-negative pathogens, this contract specifically aims at developing new antibiotics for AMR and biothreat pathogens, indicating a focus on potentially different or broader spectrum agents. Their existing pipeline and regulatory approvals demonstrate a capability in antibiotic R&D, but the success of this specific contract will depend on their ability to advance new candidates through the challenging preclinical and clinical development stages for the targeted pathogens.

How does the $72.1 million contract value compare to similar R&D investments in novel antibiotic development?

The $72.1 million contract value over approximately six years for novel antibiotic R&D is within a reasonable range for early to mid-stage drug development. Developing a new antibiotic is a lengthy and expensive process, often costing hundreds of millions to over a billion dollars through to market approval. Government contracts like this often fund specific stages or aspects of development, such as preclinical research, early-stage clinical trials, or specific target pathogen research. Compared to private sector investments or larger government grants that might cover the entire drug lifecycle, this amount represents a significant but focused investment. The Cost Plus Fixed Fee structure allows for flexibility in research scope while providing a defined profit margin, which is common in government R&D contracts.

What are the primary risks associated with this contract, and how are they being mitigated?

The primary risks associated with this contract are inherent to pharmaceutical R&D: scientific risk (failure to discover or develop a viable drug candidate), clinical risk (failure to demonstrate safety and efficacy in human trials), regulatory risk (failure to gain FDA approval), and market risk (lack of commercial viability even if approved). Mitigation strategies include the phased nature of the contract, allowing for evaluation at key milestones, the Cost Plus Fixed Fee payment structure which incentivizes efficient research while covering necessary costs, and the selection of a contractor with prior experience in antibiotic development. The long performance period also allows for adaptation to evolving scientific knowledge and potential challenges.

What is the expected program effectiveness and impact of this contract on combating antimicrobial resistance?

The expected effectiveness of this contract hinges on the successful development of a novel antibiotic that can overcome existing resistance mechanisms or target critical biothreat pathogens. If successful, the program could provide a much-needed therapeutic option against infections that are currently difficult or impossible to treat, thereby reducing morbidity and mortality associated with AMR. The impact on combating antimicrobial resistance would be significant, contributing to the global pipeline of effective treatments and potentially saving lives. However, the effectiveness is not guaranteed, as drug development has a high failure rate. The contract's success will be measured by the advancement of drug candidates through development stages and, ultimately, their potential for regulatory approval and clinical use.

How does this contract fit into the broader historical spending patterns for R&D in infectious diseases and biodefense?

This contract aligns with a long-standing and increasing trend of federal spending on infectious disease research and biodefense countermeasures. Following events like the COVID-19 pandemic and growing concerns over AMR, government agencies like HHS (specifically ASPR) have prioritized funding for novel therapeutics, diagnostics, and vaccines. Historical spending in this area has fluctuated based on perceived threats but has generally seen an upward trajectory, particularly for R&D aimed at novel antibiotics and agents against potential bioweapons. This $72.1 million award represents a specific investment within a larger portfolio of initiatives aimed at strengthening national preparedness and response capabilities against infectious disease threats.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 75A50122R00009

Offers Received: 3

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 30 SPRING MILL DR, MALVERN, PA, 19355

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $318,625,321

Exercised Options: $72,141,707

Current Obligation: $72,141,707

Actual Outlays: $22,960,455

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline